TY - JOUR
T1 - Inhibition of hepatitis B virus with the help of CRISPR/Cas9 technology
AU - Noor, Sadaf
AU - Rasul, Akhtar
AU - Iqbal, Muhammad Shahid
AU - Ahmed, Bilal
AU - Akash, Muhammad Sajid Hamid
AU - Qadir, Muhammad Imran
N1 - Publisher Copyright:
© 2020 by Begell House, Inc.
PY - 2020
Y1 - 2020
N2 - Hepatitis B infection caused by hepatitis B virus (HBV) is a serious health issue worldwide. Existing therapeutic strategies hardly eradicate HBV infections, and they fail to attain complete cure. Advanced treatment strategies are urgently needed to successfully terminate further spread of HBV infection and eliminate hidden reservoirs of virus. Recently, a novel RNA-guided gene editing tool, known as the clustered regularly interspaced short palindromic repeats/ CRISPR-associated nuclease 9 (CRISPR/Cas9) system, has been established. It facilitates site-specific mutagenesis and reveals a new way to develop applicable techniques for disease treatment, such as extermination of infectious agents like HBV. This study highlights the current developments in CRISPR/Cas9 technology and its importance for target-specific inhibition of HBV genome. Benefits, challenges, feasible solutions, and proposed guidelines for forthcoming study in CRISPR/Cas9 are described to highlight the possible cures of and treatments for chronic HBV infection.
AB - Hepatitis B infection caused by hepatitis B virus (HBV) is a serious health issue worldwide. Existing therapeutic strategies hardly eradicate HBV infections, and they fail to attain complete cure. Advanced treatment strategies are urgently needed to successfully terminate further spread of HBV infection and eliminate hidden reservoirs of virus. Recently, a novel RNA-guided gene editing tool, known as the clustered regularly interspaced short palindromic repeats/ CRISPR-associated nuclease 9 (CRISPR/Cas9) system, has been established. It facilitates site-specific mutagenesis and reveals a new way to develop applicable techniques for disease treatment, such as extermination of infectious agents like HBV. This study highlights the current developments in CRISPR/Cas9 technology and its importance for target-specific inhibition of HBV genome. Benefits, challenges, feasible solutions, and proposed guidelines for forthcoming study in CRISPR/Cas9 are described to highlight the possible cures of and treatments for chronic HBV infection.
KW - Antiviral therapy
KW - CccDNA
KW - RNA-guided gene editing
UR - https://www.scopus.com/pages/publications/85088957989
U2 - 10.1615/CritRevEukaryotGeneExpr.2020028453
DO - 10.1615/CritRevEukaryotGeneExpr.2020028453
M3 - Article
C2 - 32749114
AN - SCOPUS:85088957989
SN - 1045-4403
VL - 30
SP - 273
EP - 278
JO - Critical Reviews in Eukaryotic Gene Expression
JF - Critical Reviews in Eukaryotic Gene Expression
IS - 3
ER -
